Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety, tolerability, and pharmacokinetics study of LY3876602 in healthy participants
NL-OMON58983Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing LY3876602 with Placebo (2 arms). Primary endpoints: Safety and Tolerability. Started Aug 2023; status: completed.
02
Drugs
LY3876602
Beyond the preview
Go deeper on NL-OMON58983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58983.